TTRX (Turn Therapeutics) Ending Cash Position: $10.29 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $9.82
! 1 Warning Sign
View Full Analysis

What is Turn Therapeutics Ending Cash Position?

Turn Therapeutics TTRX -3.58% 11 Ending Cash Position is $10.29 Mil as of Jun. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Turn Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $10.29 Mil.

Turn Therapeutics's quarterly Ending Cash Position increased from Dec. 2025 ($5.08 Mil) to Mar. 2026 ($11.22 Mil) but then declined from Mar. 2026 ($11.22 Mil) to Jun. 2026 ($10.29 Mil).

Turn Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($1.18 Mil) to Dec. 2024 ($0.87 Mil) but then increased from Dec. 2024 ($0.87 Mil) to Dec. 2025 ($5.08 Mil).

Turn Therapeutics Ending Cash Position Related Terms

Turn Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Ending Cash Position Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
1.18 0.87 5.08

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.19 3.11 5.08 11.22 10.29
TTRX
11GF Score
Turn Therapeutics Inc TTRX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Turn Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.873+4.203
=5.08

Turn Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=11.218+-0.929
=10.29

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $10.29 Mil mean?
Turn Therapeutics (TTRX) has a Ending Cash Position of $10.29 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Turn Therapeutics and its competitors.
Is Turn Therapeutics' Ending Cash Position too high?
Turn Therapeutics' current Ending Cash Position is $10.29 Mil. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Ending Cash Position compare to IRD and VRXA?
Turn Therapeutics' Ending Cash Position of $10.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Turn Therapeutics and its competitors. Turn Therapeutics's current Ending Cash Position is $10.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Ending Cash Position of $10.29 Mil. The current Ending Cash Position is $10.29 Mil. Turn Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Ending Cash Position is $10.29 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.82
Price